Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate how different types of routine sedation may affect patient's breathing whilst on a ventilator in the Intensive Care Unit (ICU). There are different approaches to sedation which may have advantages and disadvantages. During the study patients will receive both intravenous and inhaled volatile sedation (similar to anaesthetic 'gases' used for general anaesthesia) and the drive to breath, breathing efforts and function of the lung will be assessed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course

NCT04014218

ARDS

UNKNOWN PHASE4

Inhalational (Sevoflurane) Versus Intravenous (Propofol) Sedation in Adults With a Moderate Form of ARDS

NCT05259631

Acute Respiratory Distress Syndrome

SUSPENDED PHASE3

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

NCT04415060

Covid19 Hypoxic Respiratory Failure

ACTIVE_NOT_RECRUITING PHASE3

SEvoflurane for Sedation in ARds

NCT04235608

Acute Respiratory Distress Syndrome

COMPLETED PHASE3

Inhaled Sedation in Critically Ill Patients

NCT07000526

Sedation Airway Extubation

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is routine for patients to be sedated for their comfort and safety whilst on a ventilator in the Intensive Care Unit (ICU). Conventionally sedatives are given intravenously, however inhaled volatile sedation is becoming more popular. Inhaled sedation has recently been approved by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK).

Whilst being on a ventilator can be life-saving, it can cause potential problems. It is important that the patient interacts well with the ventilator and that their own breathing efforts are well regulated. There is evidence that inhaled sedation can specifically help the lungs when patients have the Acute Respiratory Distress Syndrome (ARDS) and in particular, inhaled sedation does not appear to suppress patient's own breathing as much as conventional sedation. Greater spontaneous breathing by the patient is usually positive but needs to be carefully understood to ensure it is not excessive or damaging to the patient's already injured lungs.

This study of 20 patients is designed to carefully measure the impact of inhaled sedation on the patient's breathing and lung function, in comparison to intravenous sedation. Measurements will be taken whilst on intravenous sedation before the patient is switched to an equivalent level of inhaled sedation for six hours, when the measurements will be repeated. Finally, the patient will go back to their original intravenous sedation and the measurements taken again. This is called a 'cross-over' study and is a good way to evaluate the effect of the drug.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome Mechanical Ventilation Complication Sedation Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Prospective, cross-over trial design comparing intravenous versus inhaled volatile sedation

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

None, open label, physiological study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional intravenous sedation

Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.

Group Type ACTIVE_COMPARATOR

Propofol

Intervention Type DRUG

Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation

Inhaled volatile sedation

Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.

Group Type ACTIVE_COMPARATOR

Isoflurane

Intervention Type DRUG

Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol

Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation

Intervention Type DRUG

Isoflurane

Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients admitted to the Intensive Care Unit (ICU)
* ARDS
* Invasive mechanical ventilation (IMV)
* Spontaneous breathing in pressures support mode (PSV) for less than or equal to 48 hours
* Sedated with intravenous sedation (ie. propofol and / or midazolam and fentanyl or alternate short acting opioid)
* Anticipated to remain on IMV and PSV and with a stable sedation score for a further 24 hours without planned sedation interruption / spontaneous breathing trial or other significant change in the level of ventilator support
* Not receiving / anticipated to receive paralysis
* In supine position

Exclusion Criteria

* Personal or family history of malignant hyperpyrexia
* Known or suspected elevated intracranial pressure
* High dose vasopressors (ie. Noradrenaline \> 0.3mcg/kg/min or equivalent)
* Contra-indication to oesophageal balloon (i.e. oesophageal / upper gastro-intestinal pathology)
* Pregnancy
* High dose oral sedatives (e.g. benzodiazepines) or opioids (e.g. oxycodone / oral morphine) which may affect respiratory drive

Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No